These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The International Registry on Hand and Composite Tissue allotransplantation. Petruzzo P, Dubernard JM. Clin Transpl; 2011; ():247-53. PubMed ID: 22755418 [Abstract] [Full Text] [Related]
3. The international registry on hand and composite tissue transplantation. Petruzzo P, Lanzetta M, Dubernard JM, Margreiter R, Schuind F, Breidenbach W, Nolli R, Schneeberger S, van Holder C, Kaufman C, Jablecki J, Landin L, Cavadas P. Transplantation; 2008 Aug 27; 86(4):487-92. PubMed ID: 18724213 [Abstract] [Full Text] [Related]
5. Second report (1998-2006) of the International Registry of Hand and Composite Tissue Transplantation. Lanzetta M, Petruzzo P, Dubernard JM, Margreiter R, Schuind F, Breidenbach W, Nolli R, Schneeberger S, van Holder C, Gorantla VS, Pei G, Zhao J, Zhang X. Transpl Immunol; 2007 Jul 27; 18(1):1-6. PubMed ID: 17584595 [Abstract] [Full Text] [Related]
6. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Woodroffe R, Yao GL, Meads C, Bayliss S, Ready A, Raftery J, Taylor RS. Health Technol Assess; 2005 May 27; 9(21):1-179, iii-iv. PubMed ID: 15899149 [Abstract] [Full Text] [Related]
7. Outcomes after bilateral hand allotransplantation: a risk/benefit ratio analysis. Petruzzo P, Gazarian A, Kanitakis J, Parmentier H, Guigal V, Guillot M, Vial C, Dubernard JM, Morelon E, Badet L. Ann Surg; 2015 Jan 27; 261(1):213-20. PubMed ID: 24646555 [Abstract] [Full Text] [Related]
8. De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: a one-year follow-up analysis. Zucker MJ, Baran DA, Arroyo LH, Goldstein DJ, Neacy C, Mele L, Weinberg AD, Prendergast TW, Ribner HS. Transplant Proc; 2005 Jun 27; 37(5):2231-9. PubMed ID: 15964386 [Abstract] [Full Text] [Related]
14. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Sarwal MM, Vidhun JR, Alexander SR, Satterwhite T, Millan M, Salvatierra O. Transplantation; 2003 Nov 15; 76(9):1331-9. PubMed ID: 14627912 [Abstract] [Full Text] [Related]
15. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol. Jaber JJ, Feustel PJ, Elbahloul O, Conti AD, Gallichio MH, Conti DJ. Clin Transplant; 2007 Nov 15; 21(1):101-9. PubMed ID: 17302598 [Abstract] [Full Text] [Related]
16. One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient. Montini G, Murer L, Ghio L, Pietrobon B, Ginevri F, Ferraresso M, Cardillo M, Scalamogna M, Perfumo F, Edefonti A, Zanon GF, Zacchello G. Transpl Int; 2005 Jan 15; 18(1):36-42. PubMed ID: 15612981 [Abstract] [Full Text] [Related]